Theriva Biologics
TOVX
17 hedge funds and large institutions have $705K invested in Theriva Biologics in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
21% more funds holding
Funds holding: 14 → 17 (+3)
8% more capital invested
Capital invested by funds: $653K → $705K (+$52K)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$132K |
| 2 |
VF
Virtu Financial
New York
|
+$36.6K |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$23K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.52K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$30.5K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$5.17K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $474K | +$132K | +1,512 | +44% |
|
|
2
Fisher Asset Management
Camas,
Washington
| $48K | +$23K | +262 | +109% |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $42K | – | – | – |
|
|
VF
4
Virtu Financial
New York
| $40K | +$36.6K | +418 | New |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $28K | – | – | – |
|
6
William Blair & Company
Chicago,
Illinois
| $21K | +$613 | +7 | +3% |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| $14K | -$30.5K | -348 | -70% |
|
8
BlackRock
New York
| $14K | – | – | – |
|
9
Geode Capital Management
Boston,
Massachusetts
| $6K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $6K | +$5.17K | +59 | New |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6K | +$5.52K | +63 | New |
|
|
12
Northern Trust
Chicago,
Illinois
| $5K | -$5.17K | -59 | -52% |
|
|
IA
13
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
|
GWM
14
Geneos Wealth Management
Englewood,
Colorado
| – | -$2K | -20 | Closed |
|
15
Wells Fargo
San Francisco,
California
| – | +$88 | +1 | New |
|
TOVX Hedge Fund Activity: Q4 2020 in Review
17 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2020, worth a combined $705K — up 8% from $653K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TOVX positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $132K. The largest seller was Vanguard Group, cutting an estimated $30.5K.
- 17 institutional investors held Theriva Biologics (TOVX) as of Q4 2020, up from 14 in Q3 2020.
- Funds reported $705K of Theriva Biologics stock for Q4 2020, up 8% quarter-over-quarter.
- 4 funds opened new Theriva Biologics positions in Q4 2020 and 1 closed out, a net change of +3 holders.
- The largest Theriva Biologics buyer in Q4 2020 was Renaissance Technologies, an estimated $132K added.
- The largest Theriva Biologics seller in Q4 2020 was Vanguard Group, an estimated $30.5K sold.
Based on aggregated 13F filings for Q4 2020.